Patients with acute myeloid leukemia (AML) who are older and fit who get pretreated with a 10-day regimen of decitabine (Dacogen, Otsuka) before an allogeneic hematopoietic stem cell transplant have similar overall survival (OS) and fewer side effects than those who receive conventional intensive chemotherapy, according to a new study. These findings, from a phase 3 trial, were presented at the 2022 annual meeting of the European Hematology Association (abstract S125).
In the study, led by
SEPTEMBER 23, 2022